| [February 15, 2012] |
 |
RBCC Set to Go Global With n3D
NOKOMIS, Fla. --(Business Wire)--
Rainbow Biosciences LLC (OTCBB:RBCC) announced today that it has agreed
to all material terms in an equity funding agreement with n3D
Biosciences that could take the company to astonishing new heights.
The deal represents the culmination of months of due diligence,
executive-level meetings and negotiations to reach an agreement that
will drastically advance and expand n3D's business model and revenue
generation opportunities.
The agreement provides for an equity involvement by RBCC with the option
for RBCC to purchase a substantial percentage of the shares of the
company by the exercise of the conversion clause in the agreement.
N3D is a fully commercialized company that has developed a breakthrough
three-dimensional cell culturing system poised to make research into
stem cells and other disciplines faster, easier and more affordable than
ever before. This funding agreement would allow RBCC to move forward
with its global marketing initiative for n3D's product portfolio and
bring this innovative technology to researchers waiting around the world.
RBCC expects to finalize the definitive agreement before the end of next
week.
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Celgene Corp.
(NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories
(NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
Follow us on Twitter (News - Alert) at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC).
The company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit our website at [www.rainbowbiosciences.com].
For investment information and performance data on the company, please
visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
